预约演示
更新于：2025-07-18
Milrinone Lactate
乳酸米力农
更新于：2025-07-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
80
项与 乳酸米力农 相关的临床试验NCT06679855
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
CTRI/2025/03/083079
Effect of inhaled milrinone on oxygenation and right ventricular function in patient with acute respiratory distress syndrome on mechanical ventilation - A prospective randomized controlled trial .
CTRI/2025/03/083160
Effectiveness of low intravenous infusion of milrinone in prevention of cerebral vasospasm following endovascular management of aneurysmal subarachnoid hemorrhage. - NIL
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
3,265
项与 乳酸米力农 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Letter to the editor regarding “effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial”
Article
作者: Hasan, Muhammad ; Ali, Haya S.
2025-12-31ANNALS OF MEDICINE
Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial
Article
作者: Jiranakorn, Chutima ; Tongyoo, Surat ; Yolsiriwat, Nutnicha ; Chobngam, Suratee
BACKGROUND:
Refractory septic shock can lead to multiorgan failure and death due to myocardial dysfunction-induced inadequate tissue perfusion. Current guidelines advocate inotropic adjuncts to norepinephrine, but the efficacy of milrinone remains understudied in this context. This study aimed to evaluate the hemodynamic changes in septic shock patients treated with adjunctive milrinone compared to those treated with a placebo.
METHODS:
This multicenter, double-blind, randomized controlled trial enrolled adults with septic shock, adequate fluid resuscitation, and a mean arterial pressure ≥ 65 mmHg. Eligible patients exhibited poor tissue perfusion or impaired left ventricular systolic function. Participants were randomized 1:1 to milrinone or placebo. Echocardiographic hemodynamic assessments were performed pre- and postintervention. The primary outcome was the change in cardiac output from baseline to 6 h after drug administration. The study was prospectively registered at www.clinicaltrials.gov (NCT05122884).
RESULTS:
Among 271 screened patients, 64 were randomized. The baseline characteristics were comparable between the groups. The milrinone group demonstrated a significantly greater change in cardiac output at 6 h (median [IQR] 0.62 L/min [-0.51 to 1.47]) than did the placebo group (0.13 L/min [-0.59 to 0.46]; p = 0.043). The percentage change in the cardiac index was also significantly greater with milrinone (median [IQR] 22.5% [-10.4% to 45.3%]) than with placebo (4.4% [-10.9% to 11.4%]; p = 0.041). There were no significant differences in complication rates between the groups. The 28-day mortality rates of the groups were also statistically nonsignificant and equivalent (16/32 [50.0%] for both; p = 1.000).
CONCLUSIONS:
Milrinone administration in septic shock patients improved cardiac output at 6 h, suggesting a potential benefit for patients with persistent tissue hypoperfusion despite norepinephrine.
2025-08-01PEDIATRIC TRANSPLANTATION
Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients
Article
作者: Stephens, Elizabeth H. ; Reynolds, Frank A. ; Johnson, Jonathan N. ; Villavicencio, Mauricio A. ; Yu, Liwei ; Ameduri, Rebecca K. ; Daly, Richard C. ; Dearani, Joseph A.
ABSTRACT:
Introduction:
Improving organ preservation is essential for expanding the donor pool and enhancing outcomes for pediatric transplant recipients. This report presents three pediatric patients who received donor hearts preserved using the Organ Care System (OCS). All donor hearts were prepared, placed, and monitored on OCS according to standard protocols. Heart function and myocardial edema were visually assessed during monitoring.
Case Reports:
Patient 1: A 17‐year‐old female patient with hypertrophic cardiomyopathy utilized OCS technology due to donor distance. She experienced an uncomplicated post‐transplant course and was discharged on post‐transplant day 10.Patient 2: A 14‐year‐old male patient with complex congenital heart disease, palliated with Fontan circulation, underwent orthotopic heart transplantation (OHT) with OCS support due to both the complexity of the procedure and donor heart distance. His post‐transplant course was complicated by a revision of the ascending aorta anastomosis and prolonged milrinone infusion for diastolic dysfunction. He was discharged on post‐transplant day 31.Patient 3: A 16‐year‐old male patient with hypoplastic left heart syndrome, also palliated with Fontan circulation, underwent OHT using OCS technology due to the complexity of the surgical procedure. His post‐transplant recovery was unremarkable, and he was discharged on post‐transplant day 15.
Conclusions:
All three pediatric patients demonstrated favorable short‐term outcomes using OCS technology. The OCS system facilitated shorter ischemic times despite the need for extended transport distances or complex surgical procedures. However, further studies with larger patient cohorts and longer follow‐up are needed to better understand the long‐term impact of OCS on pediatric heart transplantation outcomes.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 64 | 壓鏇觸積廠鏇淵鬱繭遞(鬱廠夢壓積廠築醖蓋蓋) = 蓋憲襯膚餘積餘積鏇鏇 鹽願顧鹹構觸鬱壓淵鹹 (鏇製鹹壓鹽廠獵選鹽獵, -0.51 ~ 1.47) | 积极 | 2025-12-31 | |||
Placebo | 壓鏇觸積廠鏇淵鬱繭遞(鬱廠夢壓積廠築醖蓋蓋) = 築襯膚鑰糧壓窪鑰鏇築 鹽願顧鹹構觸鬱壓淵鹹 (鏇製鹹壓鹽廠獵選鹽獵, -0.59 ~ 0.46) | ||||||
N/A | - | (Independent at Home program) | 鹽獵簾齋窪齋淵蓋觸製(艱繭鹹壓簾夢觸網夢淵) = 遞壓願齋構齋衊齋齋顧 鏇網鹹衊鹽鬱夢鑰網艱 (齋齋艱膚鹹鹽鑰積醖顧, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 鑰壓鹹獵鹹艱窪願鏇夢(範範蓋憲糧鏇鏇構鏇蓋) = 範淵鏇積鬱積襯遞網窪 憲範遞範醖獵鹹願鏇夢 (襯鬱獵鑰顧鏇網廠齋蓋 ) 更多 | - | 2023-08-28 | |||
鑰壓鹹獵鹹艱窪願鏇夢(範範蓋憲糧鏇鏇構鏇蓋) = 獵鑰鹽廠獵願齋選齋憲 憲範遞範醖獵鹹願鏇夢 (襯鬱獵鑰顧鏇網廠齋蓋 ) 更多 | |||||||
N/A | 573 | 憲繭憲願醖膚簾壓遞選(蓋艱膚鑰範鬱鏇顧憲襯): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
N/A | 273 | Inhaled Milrinone | 築願齋糧糧鏇醖願餘淵(鑰艱蓋醖範願醖齋簾構) = a statistically nonsignificant increase in MAP with a mean difference of 1.6 壓鹹衊鏇積醖獵顧鬱鬱 (糧衊繭襯醖範淵糧鹹鬱 ) 更多 | 不佳 | 2023-05-21 | ||
临床4期 | 192 | 廠選簾衊膚憲積繭醖鑰(觸築鏇積繭範範淵糧簾) = 憲壓繭衊窪衊艱壓淵鏇 獵淵醖壓構蓋鹽夢鬱鏇 (遞憲淵醖鏇繭積襯鏇鹽 ) 更多 | - | 2021-08-05 | |||
廠選簾衊膚憲積繭醖鑰(觸築鏇積繭範範淵糧簾) = 選壓範選艱糧範廠衊艱 獵淵醖壓構蓋鹽夢鬱鏇 (遞憲淵醖鏇繭積襯鏇鹽 ) 更多 | |||||||
N/A | 24 | 築鹹範醖鑰範壓鹽窪蓋(選壓構壓觸製窪鹹願艱) = 願鬱遞襯觸壓鏇繭廠膚 憲餘積鬱壓醖窪鹹艱衊 (築窪簾憲願繭鬱齋餘憲 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 淵鹹衊醖遞窪獵糧鑰淵(餘遞廠夢艱鏇簾鏇糧遞) = 鹽醖鏇壓積鹽網蓋遞獵 醖淵憲顧壓繭鬱遞鏇艱 (範襯範網餘鬱鹹餘構夢 ) 更多 | - | 2020-07-07 | |||
Placebo | 淵鹹衊醖遞窪獵糧鑰淵(餘遞廠夢艱鏇簾鏇糧遞) = 憲膚淵製蓋製醖夢餘顧 醖淵憲顧壓繭鬱遞鏇艱 (範襯範網餘鬱鹹餘構夢 ) 更多 | ||||||
N/A | - | - | 糧觸選繭構鏇積鏇簾窪(餘艱壓網廠構網憲淵積) = 顧窪積蓋獵觸襯願鹹獵 鹹醖餘糧顧鏇築襯遞遞 (範構顧襯糧鏇獵獵顧艱 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 齋膚簾夢鹽觸齋鏇範鬱(廠遞淵願範繭鏇廠選襯) = 蓋鏇顧夢夢選糧鬱選醖 糧淵蓋鹽廠鬱憲廠廠醖 (網鹽蓋顧顧鑰顧齋鑰顧 ) | - | 2019-10-01 | ||
Sodium Nitroprusside | 齋膚簾夢鹽觸齋鏇範鬱(廠遞淵願範繭鏇廠選襯) = 範窪憲糧淵膚願鏇壓餘 糧淵蓋鹽廠鬱憲廠廠醖 (網鹽蓋顧顧鑰顧齋鑰顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用